Pahuja Anjali K, Mundodan Mahammood Suhail
Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, Delhi, India.
BMJ Case Rep. 2018 Jun 4;2018:bcr-2018-224838. doi: 10.1136/bcr-2018-224838.
An adolescent patient diagnosed with disseminated abdominal desmoplastic small round cell tumour (DSRCT) was taken up for systemic chemotherapy, debulking surgery, stem cell transplant followed by whole abdominopelvic radiotherapy using intensity-modulated radiotherapy. Following this, the patient developed multiple episodes of small bowel obstruction, a known complication of abdominal surgery and radiotherapy. The patient expired due to the complications of bowel obstruction 13 months after the completion of radiotherapy. Though we managed to achieve a complete response at the disease sites with an aggressive therapeutic approach, the patient eventually succumbed to treatment-induced morbidity. Large prospective trials to define management guidelines taking into account quality of life issues may not be feasible for a rare and aggressive scenario such as DSRCT. Therefore, case reports and series reporting not just the treatment techniques and survival, but also the resultant toxicities, will make us vigilant when choosing the intensity of its treatment.
一名被诊断为弥漫性腹部促纤维增生性小圆细胞瘤(DSRCT)的青少年患者接受了全身化疗、肿瘤减积手术、干细胞移植,随后采用调强放疗进行全腹盆腔放疗。在此之后,患者出现多次小肠梗阻,这是腹部手术和放疗的已知并发症。患者在放疗结束13个月后因肠梗阻并发症死亡。尽管我们通过积极的治疗方法在疾病部位实现了完全缓解,但患者最终还是死于治疗引起的并发症。对于DSRCT这样罕见且侵袭性强的病例,开展考虑生活质量问题的大型前瞻性试验来确定管理指南可能并不可行。因此,病例报告和系列报道不仅要报告治疗技术和生存率,还要报告由此产生的毒性,这将使我们在选择治疗强度时保持警惕。